Sponsored and organized by:


WHERE INNOVATIVE LIFE SCIENCE COMPANIES

MEET INVESTORS
// Next Edition March 1st-2nd 2022// Euro-Swiss Technopole
//Archamps//France

 

Who should attend and Why?

 

Who should attend

BioData is the yearly Swiss symposium where leaders of the Swiss and international biopharmaceutical and medical technology industry meet investors. The programme is designed to inform venture capitalists, financial analysts and fund managers responsible for asset allocation of the current issues facing the industry (see the list of financial institutions below).

The programme at a glance

The ninth edition of BioData will include keynote lectures and panel discussions with a strong focus on medical technology companies and discuss some of the factors behind the success of this industry sector. The summary programme will be available here.

Why should you participate?

•  Learn about recent industry trends that will influence your investment or business partnering decisions

•  Discover exciting new opportunities for discerning investments or business-to-business partnerships in the biopharmaceutical and medical technology sectors

•  Network with CEOs and other senior level executives from leading pharmaceutical and biotechnology companies

•  Take part in one-on-one meetings with representatives from Swiss and international companies

•  Make key business contacts in the Geneva area, one of the leading centres of research excellence in mainland Europe

BioData brings together:

•  Decision makers, CEOs and other senior level executives from

    • Leading pharmaceutical companies
    • Biotechnology companies at the cutting edge of new technologies
    • Medical technology companies
    • Other major high tech industries

•  Institutional investors such as fund managers and analysts

•  Opinion leaders with a clear vision of the major issues facing the life science industry from a scientific, ethical and economic perspective

•  Financial and business media

 

List of Financial Institutions having participated in BioData

3i Gestion

Active Advisors

Activgest

Adamant Biomedical Investments

Affentrager & Associates

AFFIX Corporate Finance

AGF Private Equity

Aisling Capital

Alexion Ventures

AlpInvest Partners N.V

Alta Berkeley

Amorcage Rhône Alpes

Apax Partners

Aravis Partners

Atlas Ventures

Auriga Partners

Avance, Basel GmbH

AXA Private Equity

Banco del Gottardo

Banexi Ventures Partners

Bank Bellevue Asset Mgt

Bank Julius Baer

Bank Leu

Bank Sal. Oppenheim & Cie

Bank Sarasin

Bank Vontobel

Banque Cantonale de Genève

Banque Cantonale Vaudoise

Banque Faisal

Banque Nationale Suisse

BB Biotech Ventures

Berna Venture

BioAlps

BioArk / CimArk

BioAssociés Sarl

Biobank Technology Ventures L

BioGestion-Fonds Bioam

Biomed Invest

Biosafe

BNP Paribas

Bordier & Cie

Breslin Biotech

Brilleon Capital

Bryan, Garnier & Co

BSI

BT&T Group

BZ Bank

Canaccord Capital

Capital Group Companies

CDC Entreprises FP Gestion

CDC Entreprises Innovation

CITCO

Citigroup

Clariden

CNCE

Coges

Creadvise

Crédit Agricole Cheuvreux

Credit Agricole Private Equity

Crédit Lyonnais

Crédit Suisse

Cukierman & Co Life Sciences

Daiwa Securities

De Pury Pictet Turrettini & Cie

Defi Gestion

Deka Investment

Developement Economic Western Switzerland

Dimension Corporate Finance

Dresdner Bank

Eclosion

Edmond de Rotshild Investment Partners

EFG Bank

Endeavours

Equinet

ERAI

E-Synergy

Euronext

European Ventures Partners

Ferrier Lullin & Cie

Fonds Européen d'Investissement

Freelancer

Gedefi Asset Management SA

Genevest Consulting group

Global Biomedical Partners

Global Life Science Ventures

Goldmann Sachs

HBM BioVentures

HealthCap

Helvea

Himalaya Capital Partners

Index Ventures

Inventages Venture Capital

Invest in Western France

JP Morgan

Landsbanki Kepler

NeoMed

New England Partners

NMT

 

 

 

Lombard Odier Darier Hentsch

Matignon Investissement et Gestion

MDL Finance

Medinsight

Kepler Equities

Merrill Lynch

Morgan Stanley

Nipralabs Investment Management

Nomura

Novartis Venture Fund

NYSE Euronext

NZB Neue Zürcher Bank

Omega Advisors

Orbimed Advisors

Oxford BioScience Partners

Panmure Gordon

Pantheon Ventures

Paul Capital Partners

Pictet & Cie

PricewaterhouseCoopers

Private Bank Switzerland

Renaissance

Robert Frazer Finance

Rodman & Renshaw

Royal Bank of Canada

Sectoral Asset Management

SG Cowen

Siparex

Sofinnova

Soyco Capital Management

Swiss Re

Swissfirst Bank

Swiss National Bank

SWX

Talentmark

ThinkEquity

Tilocor International S.A.

Truffle Venture

Turenne Capital

TVM

UBS

Unicorn Bio Tutors

Union Bancaire Privée

Venture Incubator

VI Partners AG

Vinci Capital

Vision Capital

WestLB Panmure

Widmann Associates

Wolf Research & Asset Mgt

 

 

 

 

 

 

                 


Liliane Daugny